Track topics on Twitter Track topics that are important to you
RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with carboplatin and paclitaxel may help kill more tumor cells.
- To determine the recommended dose for phase II studies of ABT-888 that can be administered in combination with carboplatin and paclitaxel in patients with advanced solid malignancies. (Part A)
- To determine the recommended dose for phase II studies of ABT-888 that can be administered in combination with carboplatin and paclitaxel in patients with advanced solid malignancies that harbor a germline BRCA1/2 mutation. (Part B) (added 04/07/09)
- To define the dose-limiting toxicity and other toxicities associated with the use of this combination.
- To obtain preliminary evidence of antitumor activity in patients treated with this combination.
- To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination.
- To conduct correlative science studies including determination of the effect of ABT-888 on carboplatin-induced DNA adduct formation in tumor specimens.
- Part A (advanced solid tumors): Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1 in course 1. Beginning in course 2 and all subsequent courses, patients receive escalating doses of oral ABT-888 twice daily on days 1-7 until the recommended phase II dose is determined. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
- Part B (advanced solid tumors/germline BRCA 1 or 2 mutation)(added 04/07/09): Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3, and oral ABT-888 twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo peripheral blood mononuclear cell collection periodically for pharmacokinetic studies, evaluation of DNA adducts, and Poly-ADP ribose (PAR) levels. Some patients undergo tumor biopsies to evaluate the intratumoral effects of this regimen.
After completion of study treatment, patients are followed for 4 weeks.
Primary Purpose: Treatment
brca1 Mutation Carrier
carboplatin, paclitaxel, veliparib
City of Hope Comprehensive Cancer Center
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-07-24T14:20:17-0400
This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin and to see how well they work in treating patients with human epidermal growth f...
This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that did not respond to previous therapy. Veliparib may stop the gro...
This phase II trial studies how well veliparib works in treating patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back or does not respond to tr...
RATIONALE: Gathering information from women who are BRCA1 or BRCA2 mutation carriers may help doctors learn how they manage cancer risk and meet the challenges of young adulthood. PURPOSE...
This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with stage IV triple-negative breast cancer and/or breast cancer (BRCA) mutat...
The risks of being a cisgender BRCA1/BRCA2 mutation carrier (BRCA1+/BRCA2+) are well documented, and recommendations to mitigate cancer risk in BRCA+ cisgender women are clear. However, there is a lac...
The carboplatin/paclitaxel doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with carboplatin dosed using the Calvert formula, yielded convi...
We present a patient with metastatic melanoma who had a complete response to second line chemotherapy with paclitaxel and carboplatin.
BRCA-1 mutation-associated triple-negative breast cancer (TNBC) has been hypothesized to exhibit a phenotype that is distinct from non-mutation carriers. We have analyzed immunohistochemically detecte...
In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy for patients with vulvar cancer. Two patients with locally advanced disease had an impressive response...
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
An injectable formulation of albumin-bound paclitaxel NANOPARTICLES.
Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.
An organoplatinum compound that possesses antineoplastic activity.
An enzyme of long-chain fatty acid synthesis, that adds a two-carbon unit from malonyl-(acyl carrier protein) to another molecule of fatty acyl-(acyl carrier protein), giving a beta-ketoacyl-(acyl carrier protein) with the release of carbon dioxide. EC 22.214.171.124.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...